[Translation] A prospective, double-blind, placebo-controlled, randomized phase III study of MEDI4736 in the adjuvant setting for completely resected non-small cell lung cancer
在完全切除(IB ≥ 4cm、II或IIIA期)的PD-L1阳性非小细胞肺癌患者中,对照安慰剂,评估MEDI4736(静脉输注一年)作为辅助治疗,对无病生存的影响。
[Translation] The effect of MEDI4736 (intravenous infusion for one year) as adjuvant therapy on disease-free survival was evaluated compared with placebo in patients with completely resected (IB ≥ 4 cm, stage II or IIIA) PD-L1-positive NSCLC.